Risk prediction for clonal cytopenia: multicenter real-world evidenceZhuoer Xie, Aref Al‐Kali, Rami S. Komrokji et al.|Blood|2024Cited by 51
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational studyCorinna La Rosa, Don J. Diamond, Flavia Chiuppesi et al.|Frontiers in Immunology|2023Cited by 7
The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal CytopeniasZhuoer Xie, Aref Al‐Kali, Alexandra N. Smith et al.|Blood|2022Cited by 6
Adoptive transfer of functional <scp>SARS‐COV</scp>‐2‐specific immunity from donor graft to hematopoietic stem cell transplant recipientsCorinna La Rosa, Monzr M. Al Malki, Flavia Chiuppesi et al.|American Journal of Hematology|2022Cited by 5
FLAG-Ida-Venetoclax vs CLIA-venetoclax for relapsed and refractory AML during a fludarabine shortage: A single center experienceJose Tinajero, Karamjeet Sandhu, Amandeep Salhotra et al.|Journal of Oncology Pharmacy Practice|2025Cited by 0